Ratings Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-12-12 pm EST			5-day change	1st Jan Change
56.28 ^USD	-0.65%		-3.58%	+9.69%

Dec. 12	Bristol Myers: increase in quarterly dividend	CF
Dec. 10	Agilent Cancer Diagnostic Assay Receives Certification to Comply with New EU Regulations	MT

Summary: Bristol-Myers Squibb Company

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Highlights: Bristol-Myers Squibb Company

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The company returns high margins, thereby supporting business profitability.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
The company is one of the best yield companies with high dividend expectations.
Sales forecast by analysts have been recently revised upwards.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses: Bristol-Myers Squibb Company

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The group shows a rather high level of debt in proportion to its EBITDA.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past twelve months, analysts' opinions have been revised negatively.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings Chart: Bristol-Myers Squibb Company

Source: Surperformance

ESG chart: Bristol-Myers Squibb Company

Source: Refinitiv

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Fundamentals	Composite Valuation	Composite Momentum	Capi. ($)
	BRISTOL-MYERS SQUIBB COMPANY				115B
	ELI LILLY AND COMPANY				717B
	NOVO NORDISK A/S				492B
	JOHNSON & JOHNSON				353B
	ABBVIE INC.				308B
	MERCK & CO., INC.				252B
	ROCHE HOLDING AG				232B
	ASTRAZENECA PLC				208B
	NOVARTIS AG				199B
	AMGEN INC.				147B
	Average				302.35B
	Weighted average by Cap.

See all sector ratings

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes